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“Preconditioning with ischemia” (PC) is the phenomenon
whereby one or more episodes of brief ischemia paradoxi-
cally renders the myocardium resistant to a later, more
sustained ischemic insult (1–3). The cardioprotection af-
forded by brief, transient ischemia is biphasic; a “first
window” of protection is manifest within the initial 5 min to
approximately 3 h of the PC stimulus, the hallmark of
which is a profound reduction of infarct size, while the
“second window” is exhibited approximately 12 to 72 h later
and is characterized by both infarct size reduction and an
attenuation of postischemic contractile dysfunction of viable
but “stunned” myocardium (2–4). Although the undoubt-
edly complex cellular mechanisms contributing to this
endogenous, protective response remain incompletely re-
solved, there is general agreement that the early, “first
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window” of PC is initiated by stimulation of multiple
G-protein–coupled receptors, mediated by kinase activa-
tion, and ultimately achieved via the phosphorylation of one
or more end effectors (2,3). While the “first” and “second
windows” share many common mechanistic features (i.e.,
proximal triggers and kinase activation) (2–4), the temporal
profile of the delayed phase of cardioprotection strongly
implicates the potential involvement of nuclear transcription
and resultant protein synthesis (4). Indeed, in a series of
elegant and comprehensive studies, Bolli, Shinmura, and
colleagues (5–7) have demonstrated that the development of
the defensive, late PC phenotype is critically dependent
upon the coordinated upregulation of two co-mediators:
inducible nitric oxide synthase and, most notably, cycloox-
ygenase (COX)-2 . Based on these studies, Bolli et al. (8)
have formulated the “COX-2 hypothesis of late PC.”
The quandary: aspirin, COX-2, and cardioprotection.
An obvious question, in addition to the issue of mecha-
nisms, is whether ischemic preconditioning is a clinically
relevant phenomenon, that is, whether brief bouts of isch-
emia evoke a protective phenotype in patients at risk of
suffering acute coronary events. In this regard, current
evidence, although not definitive, favors the concept that, as
in the experimental laboratory, brief episodes of antecedent
ischemia may confer both an early and delayed phase of
endogenous cardioprotection in the human heart (9–11).
However, if the conclusions regarding the crucial role of
COX-2 in delayed PC derived from experimental models
can be extrapolated to the clinical arena, this raises a
disturbing possibility: the benefits of delayed PC may, in
concept, be compromised in patients using the COX
inhibitor acetylsalicylic acid (ASA; aspirin) for relief of
fever, pain, and inflammation and, perhaps of greatest
concern, in the countless patients prescribed ASA for the
prophylactic prevention of acute myocardial infarction and
stroke (12–14). Moreover, as the protective role of prosta-
noids is not limited to the delayed “second window” of
preconditioning—that is, there is experimental evidence
implicating the involvement of endogenous prostaglandins
in infarct size reduction in some (15) (but not all [16])
models of early, “first window” PC, in the protection
afforded by angiotensin-converting enzyme (ACE) inhibi-
tors against postischemic myocardial stunning (17,18), and
in the reduction of infarct size seen with angiotensin1
receptor blockers (19)—ASA therapy may adversely affect
these other cardioprotective modalities. In fact, retrospec-
tive analyses of large clinical trials have suggested that the
prophylactic use of ASA may deprive the postmyocardial
infarction patient, in part, of the benefits provided by ACE
inhibitors (20,21). It is not, however, clear from these
analyses whether the potential loss of benefit related to
antithrombotic, analgesic, or antirheumatic doses of ASA.
Good news/bad news. In the current issue of the Journal,
Shinmura et al. (22) extend their previous work and address
the question of ASA therapy and cardioprotection in the
conscious rabbit model of late PC against myocardial
stunning. Using a multigroup and multidisciplinary study
design, the primary end point of late PC against stunning
was quantified by measurement of systolic wall thickening;
myocardial COX-2 protein levels were determined by
Western immunoblotting, COX-2 activity was ascertained
by measurement of prostaglandin (PG)E2 and 6-keto-
PGF1 synthesis, and in vitro platelet aggregation was
assessed using a standard, commercial platelet function
analyzer. Shinmura et al. (22) report that a single, low-dose
administration of ASA (5 mg/kg), designed to mimic
clinical antithrombotic therapy (typical daily dose of 75 to
325 mg) and confirmed by the authors to inhibit in vitro
platelet aggregation, attenuated—but did not prevent—the
increase in COX-2 activity seen with brief antecedent PC
ischemia. Most importantly, however, low-dose ASA, de-
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spite its partial inhibition of COX-2 activity, did not block
the favorable, delayed PC response (22). Similar “good
news” was obtained with three repeated doses of 10 mg/kg
ASA designed to simulate analgesic or antipyretic therapy;
no reversal of late PC against stunning was observed. In
marked contrast, “bad news” was obtained with a high,
antirheumatic dose of ASA; a single, 25 mg/kg dose of ASA
fully abrogated both the increase in COX-2 activity trig-
gered by the PC stimulus and the delayed, second window
of protection (22).
Importance and future directions. This study provides the
first experimental insight into the consequences of nonste-
roidal anti-inflammatory therapy on the efficacy of the
delayed, “second window,” of PC, and yields two important
observations: 1) late PC against stunning is maintained in
the setting of low-dose ASA therapy; but 2) a high dose of
ASA may preclude the development of this endogenous,
cardioprotective response. As a result, Shinmura et al. (22)
urge caution in the administration of high-dose ASA to
patients with coronary artery disease.
Despite the rigorous and comprehensive protocol design,
there are two caveats that warrant consideration in the
interpretation of these data. First, in addition to the care
that must always be exercised in the extrapolation of
experimental studies to the clinical setting, it must further
be acknowledged that the single, low-dose administration of
aspirin in this rabbit model does not fully mimic the
long-term, daily aspirin therapy prescribed to patients for
the primary or secondary prevention of cardiovascular
events. Second, although the age of the rabbits was not
specified, these studies were presumably conducted in adult
animals. The effects of increasing age on the delayed,
“second window” of PC are at present unknown; however,
concerns have emerged that, in some models, the efficacy of
the early, “first window,” of protection may wane, or be lost,
in senescent cohorts (23–26), while, in other species (i.e.,
rabbit), recent evidence suggests that the cellular mecha-
nisms responsible for early, “first window,” PC may differ in
adult versus old animals (27–29). As the aging cohort is,
without question, precisely the population in which the
incidence of acute ischemic events is greatest and, thus,
cardioprotection by any means (including both PC and
prophylactic aspirin therapy) is most germane, future studies
focusing on delayed PC in old animals, with versus without
aspirin therapy, would be of considerable interest and
relevance.
In addition to these aforementioned issues, the current
study raises several other compelling questions. For exam-
ple, Shinmura et al. (5) and Guo et al. (6) have previously
demonstrated that COX-2 plays a crucial role in the
evolution of both late PC against stunning and late PC
against infarction; whether aspirin therapy alters the anti-
infarct component of the delayed, “second window,” of
protection remains to be determined. Moreover, the wide-
spread clinical use of other nonsteroidal anti-inflammatory
agents with greater COX-2 specificity (i.e., ibuprofen,
naproxen) and growing popularity of recently developed
COX-2-specific inhibitors (celecoxib, rofecoxib) (30) begs
the question: do agents that more closely target COX-2
undermine the endogenous, late phase of cardioprotection
conferred by brief antecedent ischemia? This concept may,
again, be of particular relevance in aging cohorts. Finally,
although prospective clinical evaluation of these issues
would be daunting, a retrospective analysis of surrogate
indexes of delayed, “second window,” PC, incorporating use
of nonsteroidal anti-inflammatory agents as a covariate, may
provide a more feasible approach to explore the clinical
implications of the “COX-2 hypothesis of late PC.” All of
these concepts would build upon the important observations
made by Shinmura et al. (22), and represent fruitful lines of
future investigation.
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